Supplementary Figure 2: Pathway analysis in AD-MSCs and PSCs activated by Muc5ac

<p dir="ltr">Supplementary Figure 2: Pathway analysis in AD-MSCs and PSCs activated by Muc5ac. A, B) The top significantly down (A) and up (B) regulated GO pathways in AD-MSC in comparison with PSCs treated with Muc5ac-proficient (KCT3266) or deficient (KCT3266 Muc5ac KO) CM. C, D) T...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awdur: Sushil Kumar (20371917) (author)
Cyhoeddwyd: 2025
Pynciau:
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
_version_ 1849927637241167872
author Sushil Kumar (20371917)
author_facet Sushil Kumar (20371917)
author_role author
dc.creator.none.fl_str_mv Sushil Kumar (20371917)
dc.date.none.fl_str_mv 2025-11-25T00:37:35Z
dc.identifier.none.fl_str_mv 10.6084/m9.figshare.27948363.v1
dc.relation.none.fl_str_mv https://figshare.com/articles/figure/Supplementary_Figure_2_Pathway_analysis_in_AD-MSCs_and_PSCs_activated_by_Muc5ac/27948363
dc.rights.none.fl_str_mv CC BY 4.0
info:eu-repo/semantics/openAccess
dc.subject.none.fl_str_mv Cancer cell biology
pancreatic cancer
CAF heterogeneity
epigenetics
Muc5ac
stroma
dc.title.none.fl_str_mv Supplementary Figure 2: Pathway analysis in AD-MSCs and PSCs activated by Muc5ac
dc.type.none.fl_str_mv Image
Figure
info:eu-repo/semantics/publishedVersion
image
description <p dir="ltr">Supplementary Figure 2: Pathway analysis in AD-MSCs and PSCs activated by Muc5ac. A, B) The top significantly down (A) and up (B) regulated GO pathways in AD-MSC in comparison with PSCs treated with Muc5ac-proficient (KCT3266) or deficient (KCT3266 Muc5ac KO) CM. C, D) The top significantly upregulated KEGG and Reactome in the AD-MSCs (C) and PSCs (D) treated with Muc5ac-proficient (KCT3266) or deficient (KCT3266 Muc5ac KO) CM.</p>
eu_rights_str_mv openAccess
id Manara_fea0c0c876169458689689fee3ecbbfa
identifier_str_mv 10.6084/m9.figshare.27948363.v1
network_acronym_str Manara
network_name_str ManaraRepo
oai_identifier_str oai:figshare.com:article/27948363
publishDate 2025
repository.mail.fl_str_mv
repository.name.fl_str_mv
repository_id_str
rights_invalid_str_mv CC BY 4.0
spelling Supplementary Figure 2: Pathway analysis in AD-MSCs and PSCs activated by Muc5acSushil Kumar (20371917)Cancer cell biologypancreatic cancerCAF heterogeneityepigeneticsMuc5acstroma<p dir="ltr">Supplementary Figure 2: Pathway analysis in AD-MSCs and PSCs activated by Muc5ac. A, B) The top significantly down (A) and up (B) regulated GO pathways in AD-MSC in comparison with PSCs treated with Muc5ac-proficient (KCT3266) or deficient (KCT3266 Muc5ac KO) CM. C, D) The top significantly upregulated KEGG and Reactome in the AD-MSCs (C) and PSCs (D) treated with Muc5ac-proficient (KCT3266) or deficient (KCT3266 Muc5ac KO) CM.</p>2025-11-25T00:37:35ZImageFigureinfo:eu-repo/semantics/publishedVersionimage10.6084/m9.figshare.27948363.v1https://figshare.com/articles/figure/Supplementary_Figure_2_Pathway_analysis_in_AD-MSCs_and_PSCs_activated_by_Muc5ac/27948363CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/279483632025-11-25T00:37:35Z
spellingShingle Supplementary Figure 2: Pathway analysis in AD-MSCs and PSCs activated by Muc5ac
Sushil Kumar (20371917)
Cancer cell biology
pancreatic cancer
CAF heterogeneity
epigenetics
Muc5ac
stroma
status_str publishedVersion
title Supplementary Figure 2: Pathway analysis in AD-MSCs and PSCs activated by Muc5ac
title_full Supplementary Figure 2: Pathway analysis in AD-MSCs and PSCs activated by Muc5ac
title_fullStr Supplementary Figure 2: Pathway analysis in AD-MSCs and PSCs activated by Muc5ac
title_full_unstemmed Supplementary Figure 2: Pathway analysis in AD-MSCs and PSCs activated by Muc5ac
title_short Supplementary Figure 2: Pathway analysis in AD-MSCs and PSCs activated by Muc5ac
title_sort Supplementary Figure 2: Pathway analysis in AD-MSCs and PSCs activated by Muc5ac
topic Cancer cell biology
pancreatic cancer
CAF heterogeneity
epigenetics
Muc5ac
stroma